The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1

J. Su, E. Andersson, P. Horal, M. H. Naghavi, A. Palm, Y. P. Wu, K. Eriksson, M. Jansson, H. Wigzell, B. Svennerholm, A. Vahlne*

*Corresponding author for this work

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

To determine whether short peptides corresponding to the RGPGR motif of the V3 loop of gp120 have anti-human immunodeficiency virus type 1 (anti-HIV-1) activity. Design/Methods: Short peptides were tested against the HIV-1 laboratory strains and clinical isolates. Results: The tripeptide glycyl-prolyl-glycine amide (GPG-NH2) inhibited the replication of both laboratory strains and 47 clinical isolates, including 19 strains that were resistant to other drugs or that were from patients with failing therapy. The 50% inhibitory concentrations values were 2.7 to 37 μM. Phenotypic change of two isolates from nonsyncytia-inducing to syncytia-inducing did not change their sensitivity to GPG-NH2. The tripeptide added to the antiviral effect of both zidovudine and ritonavir. Conclusions: The tripeptide GPG-NH2 is a nontoxic compound that inhibits the replication of HIV-1 by an apparently new mode of action. Glycyl-prolyl-glycine-NH2 might prove useful by itself or as a lead compound for the treatment of drug-resistant HIV-1. Glycyl-prolyl-glycine-NH2 is currently undergoing phase I/II human clinical trials in Sweden.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalJournal of Human Virology
Volume4
Issue number1
StatePublished - Feb 17 2001

Keywords

  • Antiretrovirals against HIV
  • Drug resistance
  • Glycyl-prolyl-glycine
  • HIV-1 laboratory strains
  • Short peptides
  • Street strains
  • Subtypes

ASJC Scopus subject areas

  • Virology

Fingerprint Dive into the research topics of 'The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1'. Together they form a unique fingerprint.

  • Cite this

    Su, J., Andersson, E., Horal, P., Naghavi, M. H., Palm, A., Wu, Y. P., Eriksson, K., Jansson, M., Wigzell, H., Svennerholm, B., & Vahlne, A. (2001). The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1. Journal of Human Virology, 4(1), 1-7.